News and Paragraph FiveIn my initial read of the news i thought it was powerful and refreshing that it showed us shareholders some encouraging indications that the cell pouch was valid and related technologies were also highly relevant in the big picture. Historically, we have been starving for news. From there, that “writing on the wall” has since started to look like writing in neon from my point of view.
Paragraph Five:
"In the capacity of regenerative medicine lead with Sanofi, overseeing Type 1 diabetes-related collaborations and partnering, I have been closely following the preclinical and clinical advancements of Sernova's novel cell therapy technology platform approach for a number of years. I am honored and thrilled to join Sernova's Global Advisory Board as I believe Sernova is on the precipice of a 'functional cure' for several disease indications. I look forward to serving in this important and exciting new role while working alongside talented individuals and providing my expertise as these regenerative medicine products are commercialized," remarked Dr. Anke M. Schulte.
food for thought...First sentence in the paragraph speaks volumes, doesn’t it? We have been way up there in the bleachers “nosebleed” seats as we were starving for news. As much as it was frustrating I understand the need for secrecy in this case. With Dr Schulte’s career background and current job description with Sanofi, clearly the good doctor had a seat closer to the action than us in the nosebleeds. And the latter part of the first sentence seems to show that she was witness to Sernova’s progress for years. And that when there was a valid reason for Sernova to operate under a high level of secrecy. Could this mean that Sanofi and Sernova were working parallel within an agreement?? It seriously looks like it.
Now the Stockwatch headline for the news may have been a serious typo but in any case misleading. They show “Sernova appoints Schulte as advisor”. I think that it would be more correct to say “SANOFI appoints Schulte as advisor”. It all causes me to think that this food for though stuff could turn out to be a helluva feast. They seem to have all the tools and technology to get it done and out there. I believe we will be seeing the name Sanofi again at some point in the future
my optimistic opinion